{"id":20680,"date":"2016-05-23T11:39:55","date_gmt":"2016-05-23T11:39:55","guid":{"rendered":"https:\/\/www.transcrime.it\/radioligand-treatments\/"},"modified":"2016-05-23T11:39:55","modified_gmt":"2016-05-23T11:39:55","slug":"radioligand-treatments","status":"publish","type":"post","link":"https:\/\/www.transcrime.it\/en\/radioligand-treatments\/","title":{"rendered":"Radioligand treatments"},"content":{"rendered":"

Radioligand treatments (RLT) making use of Lu-177 branded PSMA is actually a good latest therapeutic approach to manage metastatic prostate disease. This treatment that is tumor-specific guided against prostate-specific membrane layer antigen (PSMA), which can be overexpressed in prostate cancer cells. In the last several years, several lutetium-177 (177Lu, \u03b2 emitter) described PSMA ligands have been designed consequently they are presently applied to treat metastatic castrate resistant prostate cancer (mCRPC) patients. But, there aren’t any potential reports released up to now by using this treatment approach in hormonal setting that is sensitive. Within this pilot research customers with hormone sensitive and painful prostate cancer tumors whom didn’t go through hormone cures shall be addressed with Lu-177 PSMA-617.
\nRadioligand treatment (RLT) is a promising latest therapeutic approach to manage metastatic prostate malignant tumors. This treatment that is tumor-specific directed against prostate-specific membrane layer antigen (PSMA),http:\/\/virtualrheumatologycentre.com\/<\/a> which will be overexpressed in prostate cancer tumors tissue. In the last several years, several lutetium-177 (177Lu, \u03b2 emitter) designated PSMA ligands have been designed and can be presently used in atomic medicine divisions worldwide to cure metastatic castrate resilient prostate cancer (mCRPC) people.<\/p>\n

A large retrospective research reported an overall biochemical impulse rate of 45% following multiple 177Lu-PSMA RLT series in mCRPC patients, while 40% of clients currently responded after having a unmarried pattern. RLT with PSMA ligand PSMA-617 was generally speaking really tolerated and 12% in the customers endured grade 3 to 4 toxicity that is hematological. In addition, moderate and xerostomia that is often transient in 8%. These listings are verified on a modest measure study that is prospective lately.<\/p>\n

Although these results are very encouraging, its popular that all currently Lu-177-PSMA-617 RLT only has been assessed in end stage prostate cancer clients up to now. In theory, RLT could be more effective in reduced quantity disease as a result of the most tumor that is high of radioligands in little lesions. There are no printed information to date assessing the restorative aftereffect of Lu-177-PSMA-617 RLT within an past period associated with the disorder. Due to the difference in tumefaction load between mCRPC people and clients with reasonable levels metastatic illness, dosimetry and poisoning within these patients want evaluation. Right Here a clinical test to investigate the efficacy of Lu-177-PSMA-617 RLT in patients with low quantity metastatic prostate disease, prior to the hormonal insensitive condition is actually proposed.<\/p>\n

Objective: The aim of this research is always to evaluate the dosimetry and toxicity of Lu-177-PSMA-617 RLT, in customers with lowest quantity, hormonal delicate prostate that is metastatic under cures situation. Eventually, the aim of this study is to stabilize formerly modern disease in these people in order to enhance the lifestyle by postponing the necessity for androgen starvation therapies (ADT).<\/p>\n","protected":false},"excerpt":{"rendered":"

Radioligand treatments (RLT) making use of Lu-177 branded PSMA is actually a good latest therapeutic approach to manage metastatic prostate disease. This treatment that is tumor-specific guided against prostate-specific membrane layer antigen (PSMA), which can be overexpressed in prostate cancer cells. In the last several years, several lutetium-177 (177Lu, \u03b2 emitter) described PSMA ligands have […]<\/p>\n","protected":false},"author":14,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[149],"tags":[],"elementi_comuni":[],"archivio_annuale_news":[],"class_list":["post-20680","post","type-post","status-publish","format-standard","hentry","category-news"],"acf":[],"yoast_head":"\nRadioligand treatments - Transcrime<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.transcrime.it\/en\/radioligand-treatments\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Radioligand treatments - Transcrime\" \/>\n<meta property=\"og:description\" content=\"Radioligand treatments (RLT) making use of Lu-177 branded PSMA is actually a good latest therapeutic approach to manage metastatic prostate disease. This treatment that is tumor-specific guided against prostate-specific membrane layer antigen (PSMA), which can be overexpressed in prostate cancer cells. In the last several years, several lutetium-177 (177Lu, \u03b2 emitter) described PSMA ligands have […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.transcrime.it\/en\/radioligand-treatments\/\" \/>\n<meta property=\"og:site_name\" content=\"Transcrime\" \/>\n<meta property=\"article:published_time\" content=\"2016-05-23T11:39:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.transcrime.it\/wp-content\/uploads\/2023\/01\/cropped-cropped-Untitled-3-07.png\" \/>\n\t<meta property=\"og:image:width\" content=\"512\" \/>\n\t<meta property=\"og:image:height\" content=\"512\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Transcrime\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@transcrime\" \/>\n<meta name=\"twitter:site\" content=\"@transcrime\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Transcrime\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.transcrime.it\\\/en\\\/radioligand-treatments\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.transcrime.it\\\/en\\\/radioligand-treatments\\\/\"},\"author\":{\"name\":\"Transcrime\",\"@id\":\"https:\\\/\\\/www.transcrime.it\\\/en\\\/#\\\/schema\\\/person\\\/a847028f9022fdee92de7929f154d1ef\"},\"headline\":\"Radioligand treatments\",\"datePublished\":\"2016-05-23T11:39:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.transcrime.it\\\/en\\\/radioligand-treatments\\\/\"},\"wordCount\":459,\"publisher\":{\"@id\":\"https:\\\/\\\/www.transcrime.it\\\/en\\\/#organization\"},\"articleSection\":[\"NEWS\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.transcrime.it\\\/en\\\/radioligand-treatments\\\/\",\"url\":\"https:\\\/\\\/www.transcrime.it\\\/en\\\/radioligand-treatments\\\/\",\"name\":\"Radioligand treatments - Transcrime\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.transcrime.it\\\/en\\\/#website\"},\"datePublished\":\"2016-05-23T11:39:55+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.transcrime.it\\\/en\\\/radioligand-treatments\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.transcrime.it\\\/en\\\/radioligand-treatments\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.transcrime.it\\\/en\\\/radioligand-treatments\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.transcrime.it\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Radioligand treatments\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.transcrime.it\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.transcrime.it\\\/en\\\/\",\"name\":\"Transcrime\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.transcrime.it\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.transcrime.it\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.transcrime.it\\\/en\\\/#organization\",\"name\":\"Transcrime\",\"url\":\"https:\\\/\\\/www.transcrime.it\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.transcrime.it\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.transcrime.it\\\/wp-content\\\/uploads\\\/2024\\\/03\\\/TC_short_version_blu_social.jpg\",\"contentUrl\":\"https:\\\/\\\/www.transcrime.it\\\/wp-content\\\/uploads\\\/2024\\\/03\\\/TC_short_version_blu_social.jpg\",\"width\":1251,\"height\":1250,\"caption\":\"Transcrime\"},\"image\":{\"@id\":\"https:\\\/\\\/www.transcrime.it\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/transcrime\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.transcrime.it\\\/en\\\/#\\\/schema\\\/person\\\/a847028f9022fdee92de7929f154d1ef\",\"name\":\"Transcrime\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/65ee0ddedf581764c63717bfebdfe8bbf3e422c5dd56d0b43475727af65dd58f?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/65ee0ddedf581764c63717bfebdfe8bbf3e422c5dd56d0b43475727af65dd58f?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/65ee0ddedf581764c63717bfebdfe8bbf3e422c5dd56d0b43475727af65dd58f?s=96&d=mm&r=g\",\"caption\":\"Transcrime\"},\"url\":\"https:\\\/\\\/www.transcrime.it\\\/en\\\/author\\\/carlo\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Radioligand treatments - Transcrime","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.transcrime.it\/en\/radioligand-treatments\/","og_locale":"en_US","og_type":"article","og_title":"Radioligand treatments - Transcrime","og_description":"Radioligand treatments (RLT) making use of Lu-177 branded PSMA is actually a good latest therapeutic approach to manage metastatic prostate disease. This treatment that is tumor-specific guided against prostate-specific membrane layer antigen (PSMA), which can be overexpressed in prostate cancer cells. In the last several years, several lutetium-177 (177Lu, \u03b2 emitter) described PSMA ligands have […]","og_url":"https:\/\/www.transcrime.it\/en\/radioligand-treatments\/","og_site_name":"Transcrime","article_published_time":"2016-05-23T11:39:55+00:00","og_image":[{"width":512,"height":512,"url":"https:\/\/www.transcrime.it\/wp-content\/uploads\/2023\/01\/cropped-cropped-Untitled-3-07.png","type":"image\/png"}],"author":"Transcrime","twitter_card":"summary_large_image","twitter_creator":"@transcrime","twitter_site":"@transcrime","twitter_misc":{"Written by":"Transcrime","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.transcrime.it\/en\/radioligand-treatments\/#article","isPartOf":{"@id":"https:\/\/www.transcrime.it\/en\/radioligand-treatments\/"},"author":{"name":"Transcrime","@id":"https:\/\/www.transcrime.it\/en\/#\/schema\/person\/a847028f9022fdee92de7929f154d1ef"},"headline":"Radioligand treatments","datePublished":"2016-05-23T11:39:55+00:00","mainEntityOfPage":{"@id":"https:\/\/www.transcrime.it\/en\/radioligand-treatments\/"},"wordCount":459,"publisher":{"@id":"https:\/\/www.transcrime.it\/en\/#organization"},"articleSection":["NEWS"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.transcrime.it\/en\/radioligand-treatments\/","url":"https:\/\/www.transcrime.it\/en\/radioligand-treatments\/","name":"Radioligand treatments - Transcrime","isPartOf":{"@id":"https:\/\/www.transcrime.it\/en\/#website"},"datePublished":"2016-05-23T11:39:55+00:00","breadcrumb":{"@id":"https:\/\/www.transcrime.it\/en\/radioligand-treatments\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.transcrime.it\/en\/radioligand-treatments\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.transcrime.it\/en\/radioligand-treatments\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.transcrime.it\/en\/"},{"@type":"ListItem","position":2,"name":"Radioligand treatments"}]},{"@type":"WebSite","@id":"https:\/\/www.transcrime.it\/en\/#website","url":"https:\/\/www.transcrime.it\/en\/","name":"Transcrime","description":"","publisher":{"@id":"https:\/\/www.transcrime.it\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.transcrime.it\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.transcrime.it\/en\/#organization","name":"Transcrime","url":"https:\/\/www.transcrime.it\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.transcrime.it\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.transcrime.it\/wp-content\/uploads\/2024\/03\/TC_short_version_blu_social.jpg","contentUrl":"https:\/\/www.transcrime.it\/wp-content\/uploads\/2024\/03\/TC_short_version_blu_social.jpg","width":1251,"height":1250,"caption":"Transcrime"},"image":{"@id":"https:\/\/www.transcrime.it\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/transcrime"]},{"@type":"Person","@id":"https:\/\/www.transcrime.it\/en\/#\/schema\/person\/a847028f9022fdee92de7929f154d1ef","name":"Transcrime","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/65ee0ddedf581764c63717bfebdfe8bbf3e422c5dd56d0b43475727af65dd58f?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/65ee0ddedf581764c63717bfebdfe8bbf3e422c5dd56d0b43475727af65dd58f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/65ee0ddedf581764c63717bfebdfe8bbf3e422c5dd56d0b43475727af65dd58f?s=96&d=mm&r=g","caption":"Transcrime"},"url":"https:\/\/www.transcrime.it\/en\/author\/carlo\/"}]}},"_links":{"self":[{"href":"https:\/\/www.transcrime.it\/en\/wp-json\/wp\/v2\/posts\/20680","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.transcrime.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.transcrime.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.transcrime.it\/en\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.transcrime.it\/en\/wp-json\/wp\/v2\/comments?post=20680"}],"version-history":[{"count":0,"href":"https:\/\/www.transcrime.it\/en\/wp-json\/wp\/v2\/posts\/20680\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.transcrime.it\/en\/wp-json\/wp\/v2\/media?parent=20680"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.transcrime.it\/en\/wp-json\/wp\/v2\/categories?post=20680"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.transcrime.it\/en\/wp-json\/wp\/v2\/tags?post=20680"},{"taxonomy":"elementi_comuni","embeddable":true,"href":"https:\/\/www.transcrime.it\/en\/wp-json\/wp\/v2\/elementi_comuni?post=20680"},{"taxonomy":"archivio_annuale_news","embeddable":true,"href":"https:\/\/www.transcrime.it\/en\/wp-json\/wp\/v2\/archivio_annuale_news?post=20680"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}